EC
CATX icon

EntryPoint Capital’s Perspective Therapeutics CATX Stock Holding History

EntryPoint Capital’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$101K Buy
+29,616
New +$112K 0.02% 743

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

EntryPoint Capital's CATX Position: Q2 2026 in Review

EntryPoint Capital opened a new position in Perspective Therapeutics (CATX) in Q2 2026: 29,616 shares worth $101K. The stake represents 0.02% of the portfolio and ranks #743 among its holdings.

132 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • EntryPoint Capital held 29,616 shares of Perspective Therapeutics worth $101K as of Q2 2026.
  • Perspective Therapeutics was a new EntryPoint Capital position in Q2 2026.
  • Perspective Therapeutics made up 0.02% of EntryPoint Capital's portfolio in Q2 2026, its #743 holding.
  • 132 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.